CFRA Research Becomes Exclusive Global Equity Research Provider for Geneva-Based Banque Audi Suisse
5.12.2024 11:00:00 CET | Business Wire | Press release
Exclusive partnership expands access to global equity research for Bank Audi Suisse team of investment professionals through CFRA’s industry-leading MarketScope Advisor Platform.
CFRA, the world’s leading provider of independent investment research today announced that its global fundamental equity, thematic, and sector research is now available to Banque Audi Suisse investment professionals and relationship managers, exclusively through their MarketScope Advisor platform.
The partnership provides Banque Audi Suisse with real-time access to CFRA’s industry-leading research and analytical tools to help their investment teams stay on top of changes in global markets, make well-informed investment decisions, and deliver value to their affluent client base.
"Our search for a global equity research provider was driven by our commitment to delivering maximum value to our client base,” said Hans Itburrun, Head of Investments for Banque Audi Suisse. “It was critical that the partner we chose be able to provide a comprehensive global view of equity markets, had a strong foundation of U.S. coverage, and was backed by a strong track record of performance, CFRA easily checked all those boxes and was able to deliver their research to our team through a turnkey, easy-to-use platform.”
"We are delighted to be selected as the exclusive provider of global equity research to Banque Audi Suisse,” says Patricia Wilson, Chief Solutions Officer for CFRA. “This strategic partnership is an important step in our focus on the Swiss market and underscores the value our research and technology offering for private banks and their clients.”
With decades of experience providing unbiased and actionable research, CFRA’s equity research is trusted globally by more than 150,000 financial advisors and relationship managers through its industry-leading MarketScope Advisor platform.
ABOUT CFRA
A global leader in financial intelligence solutions and insights, CFRA blends a proprietary mix of fundamental equity, forensic accounting, fund, public policy/legal, and technical research with data, analytics, and next-gen technology to arm clients with the financial intelligence required to meet their business and investing goals.
Learn more about CFRA Research and their MarketScope Advisor platform.
ABOUT BANQUE AUDI SUISSE
Banque Audi (Suisse) SA was first established in Zurich in 1976. Its headquarters were later relocated to Geneva, close to the city’s historic Old Town and famous lake. Operating under a Swiss banking license and under the supervision of the Swiss Financial Market Supervisory Authority (FINMA), Banque Audi Suisse offers tailor-made Private Banking services to high-net-worth clients, with access to products and foreign exchange markets all over the world.
In the latest study of November 2024 of Zurich University of Applied sciences (ZHAW) on the Best Private Banks in Switzerland in 2024, Banque Audi Suisse has been ranked as the “Best Capitalized Swiss Private Bank 2024”.
Learn more about Banque Audi Suisse.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241205074954/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom